Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADAM10 | O14672 | 20/20 | 0.76 |
| ▸ | MMP2 | P08253 | 18/20 | 0.76 |
| ▸ | ERBB2 | P04626 | 12/20 | 0.76 |
| ▸ | MMP9 | P14780 | 12/20 | 0.76 |
| ▸ | MMP3 | P08254 | 7/20 | 0.76 |
| ▸ | MMP12 | P39900 | 1/20 | 0.68 |
| ▸ | MMP14 | P50281 | 1/20 | 0.68 |
| ▸ | ADAM8 | P78325 | 1/20 | 0.68 |
| ▸ | ADAM17 | P78536 | 1/20 | 0.68 |
| ▸ | ADAM33 | Q9BZ11 | 1/20 | 0.68 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Aderbasib SCHEMBL1366560 | 1.00 | ADAM10 (0.76) | ADAM10MMP2ERBB2MMP9MMP3 | |
| SCHEMBL2528026 | 0.92 | ADAM10 (0.72) | ADAM10MMP2ERBB2MMP9MMP3 | |
| SCHEMBL2530093 | 0.92 | ADAM10 (0.72) | ADAM10MMP2ERBB2MMP9MMP3 | |
| SCHEMBL1366801 | 0.91 | ADAM10 (0.71) | ADAM10MMP2ERBB2MMP9MMP3 | |
| SCHEMBL1366083 | 0.91 | ADAM10 (0.71) | ADAM10MMP2ERBB2MMP9MMP3 | |
| SCHEMBL1364313 | 0.90 | ADAM10 (0.70) | ADAM10MMP2ERBB2MMP9MMP3 | |
| SCHEMBL3648643 | 0.90 | ADAM10 (0.79) | ADAM10MMP2ERBB2MMP9MMP3 | |
| SCHEMBL4638822 | 0.90 | ADAM10 (0.79) | ADAM10MMP2ERBB2MMP9MMP3 | |
| SCHEMBL2526870 | 0.89 | ADAM10 (0.69) | ADAM10MMP2ERBB2MMP9MMP3 | |
| SCHEMBL1365111 | 0.87 | ADAM10 (1.00) | ADAM10MMP2ERBB2MMP9MMP3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 117 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12520839-B2 | Methods and compositions for cryopreservation of cell therapies | THE GEORGE WASHINGTON UNIVERSITY (US) | 2026-01-13 | — | — | US | claimed |
| US-20250381202-A1 | PRODRUG KIT FOR MULTI-PRONGED CHEMOTHERAPY | ZOUNEK ALEX (DE) | 2025-12-18 | — | — | US | claimed |
| EP-4551565-A1 | PRODRUG KIT FOR MULTI-PRONGED CHEMOTHERAPY | Zounek, Alex (DE) | 2025-05-14 | — | — | EP | claimed |
| US-20250009852-A1 | DEPLETING EGFR AND HER2 OVERCOMES RESISTANCE TO EGFR INHIBITORS IN COLORECTAL CANCER | HEALTH RESEARCH, INC. | 2025-01-09 | — | — | US | claimed |
| CN-119185550-A | Application of ADAM10 or ADAM17 in preparation of medicine for preventing/treating membranous nephropathy | 北京中医药大学 | 2024-12-27 | — | — | CN | claimed |
| EP-4433078-A1 | DEPLETING EGFR AND HER2 OVERCOMES RESISTANCE TO EGFR INHIBITORS IN COLORECTAL CANCER | Health Research, Inc. (US) | 2024-09-25 | — | — | EP | claimed |
| WO-2024008833-A1 | PRODRUG KIT FOR MULTI-PRONGED CHEMOTHERAPY | ZOUNEK ALEX (DE) | 2024-01-11 | — | — | WO | claimed |
| WO-2023196958-A2 | TUMOR AND CANCER TARGETING COMPOUNDS | ONCOLINX PHARMACEUTICALS (US) | 2023-10-12 | — | — | WO | claimed |
| US-11674182-B2 | Biomarker for HER2-positive cancer and anti-HER2 therapy and applications thereof | INDUSTRY-UNIVERSITY COOPERATION FOUNDATION HANYANG UNIVERSITY (KR) | 2023-06-13 | — | — | US | claimed |
| WO-2023091929-A1 | DEPLETING EGFR AND HER2 OVERCOMES RESISTANCE TO EGFR INHIBITORS IN COLORECTAL CANCER | HEALTH RESEARCH, INC. (US) | 2023-05-25 | — | — | WO | claimed |
| US-20230101403-A1 | METHOD OF TREATING OR AMELIORATING CANCERS DRIVEN BY RECEPTOR TYROSINE KINASE FUSION ONCOGENES, AND COMPOSITIONS FOR THE SAME | UNIV PENNSYLVANIA (US) | 2023-03-30 | — | — | US | claimed |
| US-20220394971-A1 | METHODS AND COMPOSITIONS FOR CRYOPRESERVATION OF CELL THERAPIES | THE GEORGE WASHINGTON UNIVERSITY | 2022-12-15 | — | — | US | claimed |
| US-20140187530-A1 | AZA Spiro Alkane Derivatives as Inhibitors of Metalloproteases | INCYTE CORPORATION (US) | 2014-07-03 | — | — | US | claimed |
| US-8088737-B2 | Treating a cancer, in particular breast cancer, that overexpresses Her-2 by administering an ADAM inhibitor; novel variants of ADAM15 and ADAM15; synergistic effect between inhibition of Her-2 cleavage by an ADAM and certain cytostatic (e.g., Herceptin) and cytotoxic (e.g., Taxol) compounds | INCYTE CORPORATION (US) | 2012-01-03 | — | — | US | claimed |
| US-8039471-B2 | Aza spiro alkane derivatives as inhibitors of metalloproteases | INCYTE CORPORATION (US) | 2011-10-18 | — | — | US | claimed |
| US-7910108-B2 | Sheddase inhibitors combined with CD30-binding immunotherapeutics for the treatment of CD30 positive diseases | INCYTE CORPORATION (US) | 2011-03-22 | — | — | US | claimed |
| US-7723349-B2 | N-hydroxy-5-methyl-6-{[4-(3-methylphenyl)piperazin-1-yl]carbonyl}-5-azaspiro[2.5]octane-7-carboxamide for example; treating arthritis, cancer, cardiovascular disorders, skin disorders, inflammation and allergic conditions | INCYTE CORPORATION (US) | 2010-05-25 | — | — | US | claimed |
| US-20070280943-A1 | SHEDDASE INHIBITORS COMBINED WITH CD30-BINDING IMMUNOTHERAPEUTICS FOR THE TREATMENT OF CD30 POSITIVE DISEASES | INCYTE CORPORATION | 2007-12-06 | — | — | US | claimed |
| US-20040259896-A1 | N-hydroxy-5-methyl-6-{[4-(3-methylphenyl)piperazin-1-yl]carbonyl}-5-azaspiro[2.5]octane-7-carboxamide for example; treating arthritis, cancer, cardiovascular disorders, skin disorders, inflammation and allergic conditions | INCYTE CORPORATION | 2004-12-23 | — | — | US | claimed |
| US-20260139061-A1 | TREATMENT OF CANCER USING HUMANIZED ANTI-EGFRvIII CHIMERIC ANTIGEN RECEPTOR | NOVARTIS AG (CH) | 2026-05-21 | — | — | US | disclosed |
| US-12624118-B2 | Trispecific binding molecules against BCMA and uses thereof | NOVARTIS AG (CH) | 2026-05-12 | — | — | US | disclosed |
| US-12616733-B2 | XBP1, CD138, and CS1 peptides, pharmaceutical compositions that include the peptides, and methods of using such peptides and compositions | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2026-05-05 | — | — | US | disclosed |
| EP-4714966-A2 | CHIMERIC ENGULFMENT RECEPTOR MOLECULES AND METHODS OF USE | Cero Therapeutics Holdings, Inc. (US) | 2026-03-25 | — | — | EP | disclosed |
| US-20260077015-A1 | CELLULAR IMMUNOTHERAPY COMPOSITIONS AND USES THEREOF | CERO THERAPEUTICS HOLDINGS INC (US) | 2026-03-19 | — | — | US | disclosed |
| EP-4376874-B1 | CHIMERIC TIM4 RECEPTORS AND USES THEREOF | CERO THERAPEUTICS HOLDINGS INC (US) | 2026-03-04 | — | — | EP | disclosed |
| US-12559562-B2 | Treatment of cancer using humanized anti-EGFRvIII chimeric antigen receptor | NOVARTIS AG (CH) | 2026-02-24 | — | — | US | disclosed |
| US-12520839-B2 | Methods and compositions for cryopreservation of cell therapies | THE GEORGE WASHINGTON UNIVERSITY (US) | 2026-01-13 | — | — | US | disclosed |
| US-20250381202-A1 | PRODRUG KIT FOR MULTI-PRONGED CHEMOTHERAPY | ZOUNEK ALEX (DE) | 2025-12-18 | — | — | US | disclosed |
| EP-3688032-B1 | CHIMERIC ENGULFMENT RECEPTOR MOLECULES AND METHODS OF USE | CERO THERAPEUTICS HOLDINGS INC (US) | 2025-11-05 | — | — | EP | disclosed |
| US-12454520-B2 | Protein degraders and uses thereof | KYMERA THERAPEUTICS, INC. (US) | 2025-10-28 | — | — | US | disclosed |
| US-20250250315-A1 | CHIMERIC TIM4 RECEPTORS AND USES THEREOF | CERO THERAPEUTICS HOLDINGS INC (US) | 2025-08-07 | — | — | US | disclosed |
| US-20250214969-A1 | PROTEIN DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2025-07-03 | — | — | US | disclosed |
| US-20250195575-A1 | CHIMERIC TIM RECEPTORS AND USES THEREOF | CERO THERAPEUTICS HOLDINGS, INC. | 2025-06-19 | — | — | US | disclosed |
| CN-110787285-B | XBP1, CD138 and CS1 peptides, pharmaceutical compositions comprising the peptides, and methods of using the peptides and compositions | 达纳-法伯癌症研究所股份有限公司 | 2025-06-13 | — | — | CN | disclosed |
| US-20250186491-A1 | COMPOSITIONS AND METHODS FOR TREATING CANCER WITH CHIMERIC TIM RECEPTORS IN COMBINATION WITH INHIBITORS OF POLY (ADP-RIBOSE) POLYMERASE | CERO THERAPEUTICS HOLDINGS, INC. | 2025-06-12 | — | — | US | disclosed |
| CN-120077031-A | Prodrug kit for multitube concurrent chemotherapy | 亚历克斯·祖内克 | 2025-05-30 | — | — | CN | disclosed |
| US-12303551-B2 | Cellular immunotherapy compositions and uses thereof | CERO THERAPEUTICS HOLDINGS, INC. (US) | 2025-05-20 | — | — | US | disclosed |
| EP-4551565-A1 | PRODRUG KIT FOR MULTI-PRONGED CHEMOTHERAPY | Zounek, Alex (DE) | 2025-05-14 | — | — | EP | disclosed |
| WO-2025096952-A1 | SCAFFOLDS AND SCAFFOLD HOLDERS FOR TISSUE ENGINEERING | UNIVERSITY OF CONNECTICUT (US) | 2025-05-08 | — | — | WO | disclosed |
| US-12291557-B2 | Chimeric TIM4 receptors and uses thereof | CERO THERAPEUTICS HOLDINGS, INC. (US) | 2025-05-06 | — | — | US | disclosed |
| US-20250127896-A1 | CHIMERIC TIM4 RECEPTORS AND USES THEREOF | CERO THERAPEUTICS HOLDINGS, INC. | 2025-04-24 | — | — | US | disclosed |
| US-20250018031-A1 | PEPTIDE VACCINES AND PEMBROLIZUMAB FOR TREATING BREAST CANCER | ONCOPEP INC (US) | 2025-01-16 | — | — | US | disclosed |
| US-20250009852-A1 | DEPLETING EGFR AND HER2 OVERCOMES RESISTANCE TO EGFR INHIBITORS IN COLORECTAL CANCER | HEALTH RESEARCH, INC. | 2025-01-09 | — | — | US | disclosed |
| CN-119185550-A | Application of ADAM10 or ADAM17 in preparation of medicine for preventing/treating membranous nephropathy | 北京中医药大学 | 2024-12-27 | — | — | CN | disclosed |
| US-20240368244-A1 | CHIMERIC ENGULFMENT RECEPTOR MOLECULES | CERO THERAPEUTICS HOLDINGS, INC. | 2024-11-07 | — | — | US | disclosed |
| US-20240360243-A1 | ANTIBODIES AGAINST THE ECTODOMAIN OF ERBB3 AND USES THEREOF | ELEVATION ONCOLOGY, INC. | 2024-10-31 | — | — | US | disclosed |
| EP-4433078-A1 | DEPLETING EGFR AND HER2 OVERCOMES RESISTANCE TO EGFR INHIBITORS IN COLORECTAL CANCER | Health Research, Inc. (US) | 2024-09-25 | — | — | EP | disclosed |
| CN-111386284-B | Chimeric phagocytic receptor molecules and methods of use | 森罗治疗公司 | 2024-08-30 | — | — | CN | disclosed |
| US-20240285684-A1 | ANTI-CD72 CHIMERIC RECEPTORS AND USES THEREOF | CERO THERAPEUTICS HOLDINGS, INC. | 2024-08-29 | — | — | US | disclosed |
| US-20240285682-A1 | CHIMERIC TIM RECEPTORS AND USES THEREOF | CERO THERAPEUTICS HOLDINGS, INC. | 2024-08-29 | — | — | US | disclosed |
| US-12059463-B2 | Peptide vaccines and pembrolizumab for treating breast cancer | ONCOPEP, INC. (US) | 2024-08-13 | — | — | US | disclosed |
| US-20240238396-A1 | TREATMENT OF CANCER USING HUMANIZED ANTI-EGFRvIII CHIMERIC ANTIGEN RECEPTOR | NOVARTIS AG (CH) | 2024-07-18 | — | — | US | disclosed |
| US-12006329-B2 | Protein degraders and uses thereof | KYMERA THERAPEUTICS, INC. (US) | 2024-06-11 | — | — | US | disclosed |
| EP-4376874-A1 | CHIMERIC TIM4 RECEPTORS AND USES THEREOF | Cero Therapeutics, Inc. (US) | 2024-06-05 | — | — | EP | disclosed |
| US-20240174766-A1 | CHIMERIC ENGULFMENT RECEPTOR MOLECULES AND METHODS OF USE | CERO THERAPEUTICS HOLDINGS, INC. | 2024-05-30 | — | — | US | disclosed |
| CN-118043067-A | Chimeric TIM4 receptors and uses thereof | 森罗治疗公司 | 2024-05-14 | — | — | CN | disclosed |
| US-20240058446-A1 | CHIMERIC TIM4 RECEPTORS AND USES THEREOF | CERO THERAPEUTICS HOLDINGS, INC. | 2024-02-22 | — | — | US | disclosed |
| US-20240050473-A1 | COMPOSITIONS OF GUANYLYL CYCLASE C (GCC) ANTIGEN BINDING AGENTS AND METHODS OF USE THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2024-02-15 | — | — | US | disclosed |
| WO-2024008833-A1 | PRODRUG KIT FOR MULTI-PRONGED CHEMOTHERAPY | ZOUNEK ALEX (DE) | 2024-01-11 | — | — | WO | disclosed |
| US-11865167-B2 | Treatment of cancer using humanized anti-EGFRvIII chimeric antigen receptor | NOVARTIS AG (CH) | 2024-01-09 | — | — | US | disclosed |
| EP-4298114-A1 | LYMPHOCYTE TARGETED LENTIVIRAL VECTORS | Kelonia Therapeutics, Inc. (US) | 2024-01-03 | — | — | EP | disclosed |
| CN-110036033-B | Chimeric phagocytic receptor molecules | 森罗治疗公司 | 2023-12-08 | — | — | CN | disclosed |
| CN-117203223-A | Lymphocyte targeting lentiviral vectors | 凯洛尼亚疗法有限公司 | 2023-12-08 | — | — | CN | disclosed |
| US-20230366035-A1 | BIOMARKER FOR HER2-POSITIVE CANCER AND ANTI-HER2 THERAPY AND APPLICATIONS THEREOF | INDUSTRY-UNIVERSITY COOPERATION FOUNDATION HANYANG UNIVERSITY (KR) | 2023-11-16 | — | — | US | disclosed |
| US-20230366035-A1 | BIOMARKER FOR HER2-POSITIVE CANCER AND ANTI-HER2 THERAPY AND APPLICATIONS THEREOF | INDUSTRY-UNIVERSITY COOPERATION FOUNDATION HANYANG UNIVERSITY (KR) | 2023-11-16 | — | — | US | disclosed |
| US-20230366035-A1 | BIOMARKER FOR HER2-POSITIVE CANCER AND ANTI-HER2 THERAPY AND APPLICATIONS THEREOF | INDUSTRY-UNIVERSITY COOPERATION FOUNDATION HANYANG UNIVERSITY (KR) | 2023-11-16 | — | — | US | disclosed |
| EP-4259656-A1 | COMPOSITIONS OF GUANYLYL CYCLASE C (GCC) ANTIGEN BINDING AGENTS AND METHODS OF USE THEREOF | Takeda Pharmaceutical Company Limited (JP) | 2023-10-18 | — | — | EP | disclosed |
| US-20230285576-A1 | TREATMENT OF CANCER USING A CYCLODEXTRIN-CONTAINING POLYMER-TOPOISOMERASE INHIBITOR CONJUGATE AND A PARP INHIBITOR | ELLIPSES PHARMA LTD (GB) | 2023-09-14 | — | — | US | disclosed |
| CN-116601167-A | Compositions of Guanylate Cyclase C (GCC) antigen binding agents and methods of use thereof | 武田药品工业株式会社 | 2023-08-15 | — | — | CN | disclosed |
| US-11708423-B2 | Chimeric engulfment receptor molecules and methods of use | CERO THERAPEUTICS, INC. (US) | 2023-07-25 | — | — | US | disclosed |
| CN-116390936-A | Chimeric TIM receptors and uses thereof | 森罗治疗公司 | 2023-07-04 | — | — | CN | disclosed |
| EP-4196151-A1 | COMPOSITIONS AND METHODS FOR TREATING CANCER WITH CHIMERIC TIM RECEPTORS IN COMBINATION WITH INHIBITORS OF POLY (ADP-RIBOSE) POLYMERASE | Cero Therapeutics, Inc. (US) | 2023-06-21 | — | — | EP | disclosed |
| EP-4196152-A1 | CHIMERIC TIM RECEPTORS AND USES THEREOF | Cero Therapeutics, Inc. (US) | 2023-06-21 | — | — | EP | disclosed |
| EP-4196150-A1 | ANTI-CD72 CHIMERIC RECEPTORS AND USES THEREOF | Cero Therapeutics, Inc. (US) | 2023-06-21 | — | — | EP | disclosed |
| EP-4192509-A1 | TREATMENT OF CANCER USING A CYCLODEXTRIN-CONTAINING POLYMER-TOPOISOMERASE INHIBITOR CONJUGATE AND A PARP INHIBITOR | Ellipses Pharma Ltd (GB) | 2023-06-14 | — | — | EP | disclosed |
| US-11674182-B2 | Biomarker for HER2-positive cancer and anti-HER2 therapy and applications thereof | INDUSTRY-UNIVERSITY COOPERATION FOUNDATION HANYANG UNIVERSITY (KR) | 2023-06-13 | — | — | US | disclosed |
| US-11674182-B2 | Biomarker for HER2-positive cancer and anti-HER2 therapy and applications thereof | INDUSTRY-UNIVERSITY COOPERATION FOUNDATION HANYANG UNIVERSITY (KR) | 2023-06-13 | — | — | US | disclosed |
| US-11674182-B2 | Biomarker for HER2-positive cancer and anti-HER2 therapy and applications thereof | INDUSTRY-UNIVERSITY COOPERATION FOUNDATION HANYANG UNIVERSITY (KR) | 2023-06-13 | — | — | US | disclosed |
| WO-2023091929-A1 | DEPLETING EGFR AND HER2 OVERCOMES RESISTANCE TO EGFR INHIBITORS IN COLORECTAL CANCER | HEALTH RESEARCH, INC. (US) | 2023-05-25 | — | — | WO | disclosed |
| US-11655282-B2 | Chimeric engulfment receptor molecules | CERO THERAPEUTICS, INC. (US) | 2023-05-23 | — | — | US | disclosed |
| US-20230128499-A1 | BISPECIFIC COMBINATION THERAPY FOR TREATING PROLIFERATIVE DISEASES AND AUTOIMMUNE DISEASES | NOVARTIS AG (CH) | 2023-04-27 | — | — | US | disclosed |
| US-11623932-B2 | Protein degraders and uses thereof | KYMERA THERAPEUTICS, INC. (US) | 2023-04-11 | — | — | US | disclosed |
| US-20230101403-A1 | METHOD OF TREATING OR AMELIORATING CANCERS DRIVEN BY RECEPTOR TYROSINE KINASE FUSION ONCOGENES, AND COMPOSITIONS FOR THE SAME | UNIV PENNSYLVANIA (US) | 2023-03-30 | — | — | US | disclosed |
| WO-2022036287-A9 | ANTI-CD72 CHIMERIC RECEPTORS AND USES THEREOF | CERO THERAPEUTICS, INC. (US) | 2023-02-16 | — | — | WO | disclosed |
| EP-4126241-A1 | BISPECIFIC COMBINATION THERAPY FOR TREATING PROLIFERATIVE DISEASES AND AUTOIMMUNE DISORDERS | Novartis AG (CH) | 2023-02-08 | — | — | EP | disclosed |
| WO-2023010097-A1 | CHIMERIC TIM4 RECEPTORS AND USES THEREOF | CERO THERAPEUTICS, INC. (US) | 2023-02-02 | — | — | WO | disclosed |
| US-20220409612-A1 | TREATMENT OF CANCER | ELLIPSES PHARMA LTD (GB) | 2022-12-29 | — | — | US | disclosed |
| US-20220396631-A1 | TRISPECIFIC BINDING MOLECULES AGAINST BCMA AND USES THEREOF | NOVARTIS AG (CH) | 2022-12-15 | — | — | US | disclosed |
| US-20220394971-A1 | METHODS AND COMPOSITIONS FOR CRYOPRESERVATION OF CELL THERAPIES | THE GEORGE WASHINGTON UNIVERSITY | 2022-12-15 | — | — | US | disclosed |
| US-20220387441-A1 | TARGETING THE NEUROLIGIN-3 BINDING PARTNER CSPG4 IN GLIOMA | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY | 2022-12-08 | — | — | US | disclosed |
| US-20220370440-A1 | 4-SUBSTITUTED PYRROLO[2,3-B]PYRIDINE AS ERBB MODULATORS USEFUL FOR TREATING CANCER | LEAD DISCOVERY CENTER GMBH (DE) | 2022-11-24 | — | — | US | disclosed |
| EP-4089116-A1 | CHIMERIC ENGULFMENT RECEPTOR MOLECULES | Cero Therapeutics, Inc. (US) | 2022-11-16 | — | — | EP | disclosed |
| US-11446398-B2 | Regulated biocircuit systems | OBSIDIAN THERAPEUTICS, INC. (US) | 2022-09-20 | — | — | US | disclosed |
| WO-2022183072-A1 | LYMPHOCYTE TARGETED LENTIVIRAL VECTORS | KELONIA THERAPEUTICS, INC. (US) | 2022-09-01 | — | — | WO | disclosed |
| CN-113004390-B | Application of ADAM17 as receptor of hog cholera virus | 中国科学院动物研究所 | 2022-08-26 | — | — | CN | disclosed |
| EP-4038097-A1 | CHIMERIC TIM4 RECEPTORS AND USES THEREOF | Cero Therapeutics, Inc. (US) | 2022-08-10 | — | — | EP | disclosed |
| US-11408885-B2 | Compositions and multiplex assays for characterizing active proteases and their inhibitors | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2022-08-09 | — | — | US | disclosed |
| EP-3807274-B1 | 4-SUBSTITUTED PYRROLO[2,3-B]PYRIDINE AS ERBB MODULATORS USEFUL FOR TREATING CANCER | LEAD DISCOVERY CENTER GMBH (DE) | 2022-07-27 | — | — | EP | disclosed |
| US-20220204642-A1 | ANTIBODIES AGAINST THE ECTODOMAIN OF ERBB3 AND USES THEREOF | ELEVATION ONCOLOGY, INC. | 2022-06-30 | — | — | US | disclosed |
| WO-2022123316-A1 | COMPOSITIONS OF GUANYLYL CYCLASE C (GCC) ANTIGEN BINDING AGENTS AND METHODS OF USE THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2022-06-16 | — | — | WO | disclosed |
| US-20220098273-A1 | CHIMERIC ENGULFMENT RECEPTOR MOLECULES | CERO THERAPEUTICS HOLDINGS, INC. | 2022-03-31 | — | — | US | disclosed |
| EP-3519441-B1 | CHIMERIC ENGULFMENT RECEPTOR MOLECULES | CERO THERAPEUTICS INC (US) | 2022-03-30 | — | — | EP | disclosed |
| EP-3972634-A2 | TRISPECIFIC BINDING MOLECULES AGAINST BCMA AND USES THEREOF | Novartis AG (CH) | 2022-03-30 | — | — | EP | disclosed |
| CN-114173810-A | Trispecific binding molecules directed against BCMA and uses thereof | 诺华股份有限公司 | 2022-03-11 | — | — | CN | disclosed |
| WO-2022036265-A1 | CHIMERIC TIM RECEPTORS AND USES THEREOF | CERO THERAPEUTICS, INC. (US) | 2022-02-17 | — | — | WO | disclosed |
| WO-2022036285-A1 | COMPOSITIONS AND METHODS FOR TREATING CANCER WITH CHIMERIC TIM RECEPTORS IN COMBINATION WITH INHIBITORS OF POLY (ADP-RIBOSE) POLYMERASE | CERO THERAPEUTICS, INC. (US) | 2022-02-17 | — | — | WO | disclosed |
| WO-2022036287-A1 | ANTI-CD72 CHIMERIC RECEPTORS AND USES THEREOF | CERO THERAPEUTICS, INC. (US) | 2022-02-17 | — | — | WO | disclosed |
| EP-3946635-A2 | LOCALLY ACTING TOLL-LIKE RECEPTOR 7 (TLR7) AND/OR TLR8 AGONIST IMMUNOTHERAPY COMPOUNDS AND THEIR USES | ALTIMMUNE UK LIMITED (GB) | 2022-02-09 | — | — | EP | disclosed |
| US-20210010084-A1 | BIOMARKER FOR HER2-POSITIVE CANCER AND ANTI-HER2 THERAPY AND APPLICATIONS THEREOF | INDUSTRY-UNIVERSITY COOPERATION FOUNDATION HANYANG UNIVERSITY (KR) | 2021-01-14 | — | — | US | disclosed |
| US-9403775-B2 | AZA spiro alkane derivatives as inhibitors of metalloproteases | INCYTE CORPORATION (US) | 2016-08-02 | — | — | US | disclosed |
| US-20140187530-A1 | AZA Spiro Alkane Derivatives as Inhibitors of Metalloproteases | INCYTE CORPORATION (US) | 2014-07-03 | — | — | US | disclosed |
| US-20110288068-A1 | AZA SPIRO ALKANE DERIVATIVES AS INHIBITORS OF METALLOPROTEASES | INCYTE CORPORATION | 2011-11-24 | — | — | US | disclosed |
| US-8039471-B2 | Aza spiro alkane derivatives as inhibitors of metalloproteases | INCYTE CORPORATION (US) | 2011-10-18 | — | — | US | disclosed |
| US-7910108-B2 | Sheddase inhibitors combined with CD30-binding immunotherapeutics for the treatment of CD30 positive diseases | INCYTE CORPORATION (US) | 2011-03-22 | — | — | US | disclosed |
| US-7723349-B2 | N-hydroxy-5-methyl-6-{[4-(3-methylphenyl)piperazin-1-yl]carbonyl}-5-azaspiro[2.5]octane-7-carboxamide for example; treating arthritis, cancer, cardiovascular disorders, skin disorders, inflammation and allergic conditions | INCYTE CORPORATION (US) | 2010-05-25 | — | — | US | disclosed |
| US-20070280943-A1 | SHEDDASE INHIBITORS COMBINED WITH CD30-BINDING IMMUNOTHERAPEUTICS FOR THE TREATMENT OF CD30 POSITIVE DISEASES | INCYTE CORPORATION | 2007-12-06 | — | — | US | disclosed |
| US-20040259896-A1 | N-hydroxy-5-methyl-6-{[4-(3-methylphenyl)piperazin-1-yl]carbonyl}-5-azaspiro[2.5]octane-7-carboxamide for example; treating arthritis, cancer, cardiovascular disorders, skin disorders, inflammation and allergic conditions | INCYTE CORPORATION | 2004-12-23 | — | — | US | disclosed |
| US-20040259896-A1 | N-hydroxy-5-methyl-6-{[4-(3-methylphenyl)piperazin-1-yl]carbonyl}-5-azaspiro[2.5]octane-7-carboxamide for example; treating arthritis, cancer, cardiovascular disorders, skin disorders, inflammation and allergic conditions | INCYTE CORPORATION | 2004-12-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (22 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250381202-A1 | PRODRUG KIT FOR MULTI-PRONGED CHEMOTHERAPY | KIT, CTSL, PAICS | ADAM10 337/4885MMP2 990/4885ERBB2 165/4885 |
| US-20230285576-A1 | TREATMENT OF CANCER USING A CYCLODEXTRIN-CONTAINING POLYMER-TOPOISOMERASE INHIBITOR CONJUGATE AND A PARP INHIBITOR | PARP1, TOP1, PARP2 | ADAM10 271/4885MMP2 1736/4885ERBB2 2050/4885 |
| US-12006329-B2 | Protein degraders and uses thereof | MDM2, CUL1, PSMG3 | ADAM10 767/4885MMP2 1830/4885ERBB2 1366/4885 |
| US-20230128499-A1 | BISPECIFIC COMBINATION THERAPY FOR TREATING PROLIFERATIVE DISEASES AND AUTOIMMUNE DISEASES | CD2, CD22, CD2BP2 | ADAM10 3624/4885MMP2 4010/4885ERBB2 106/4885 |
| US-20110288068-A1 | AZA SPIRO ALKANE DERIVATIVES AS INHIBITORS OF METALLOPROTEASES | MMP9, MMP3, MMP12 | ADAM10 29/4885MMP2 23/4885ERBB2 2841/4885 |
| US-20260139061-A1 | TREATMENT OF CANCER USING HUMANIZED ANTI-EGFRvIII CHIMERIC ANTIGEN RECEPTOR | EGFR, ERBB2, HAVCR2 | ADAM10 2098/4885MMP2 2770/4885ERBB2 2/4885 |
| US-20210010084-A1 | BIOMARKER FOR HER2-POSITIVE CANCER AND ANTI-HER2 THERAPY AND APPLICATIONS THEREOF | ADAM10, ADAM17, MMP20 | ADAM10 1/4885MMP2 196/4885ERBB2 9/4885 |
| US-12454520-B2 | Protein degraders and uses thereof | MDM2, CUL1, PSMG3 | ADAM10 767/4885MMP2 1830/4885ERBB2 1366/4885 |
| US-12616733-B2 | XBP1, CD138, and CS1 peptides, pharmaceutical compositions that include the peptides, and methods of using such peptides and compositions | XBP1, MCL1, CD81 | ADAM10 4319/4885MMP2 3955/4885ERBB2 2073/4885 |
| US-11674182-B2 | Biomarker for HER2-positive cancer and anti-HER2 therapy and applications thereof | ADAM10, ADAM17, MMP20 | ADAM10 1/4885MMP2 196/4885ERBB2 9/4885 |
| US-11623932-B2 | Protein degraders and uses thereof | MDM2, CUL1, PSMG3 | ADAM10 767/4885MMP2 1830/4885ERBB2 1366/4885 |
| US-20220396631-A1 | TRISPECIFIC BINDING MOLECULES AGAINST BCMA AND USES THEREOF | CD2, CD2BP2, CD22 | ADAM10 699/4885MMP2 2899/4885ERBB2 157/4885 |
| US-12624118-B2 | Trispecific binding molecules against BCMA and uses thereof | CD2, CD40, CD22 | ADAM10 1210/4885MMP2 2315/4885ERBB2 244/4885 |
| US-20250214969-A1 | PROTEIN DEGRADERS AND USES THEREOF | MDM2, CUL1, PSMG3 | ADAM10 767/4885MMP2 1830/4885ERBB2 1366/4885 |
| US-20140187530-A1 | AZA Spiro Alkane Derivatives as Inhibitors of Metalloproteases | MMP9, MMP3, MMP12 | ADAM10 29/4885MMP2 23/4885ERBB2 2841/4885 |
| US-20220409612-A1 | TREATMENT OF CANCER | DDX1, CDC73, CBX2 | ADAM10 2859/4885MMP2 3514/4885ERBB2 1026/4885 |
| US-20230366035-A1 | BIOMARKER FOR HER2-POSITIVE CANCER AND ANTI-HER2 THERAPY AND APPLICATIONS THEREOF | ADAM10, ADAM17, MMP20 | ADAM10 1/4885MMP2 196/4885ERBB2 9/4885 |
| US-20040259896-A1 | N-hydroxy-5-methyl-6-{[4-(3-methylphenyl)piperazin-1-yl]carbonyl}-5-azaspiro[2.5]octane-7-carboxamide for example; treating arthritis, cancer, cardiovascular disorders, skin disorders, inflammation and allergic conditions | MMP9, MMP25, HDAC5 | ADAM10 258/4885MMP2 41/4885ERBB2 2369/4885 |
| US-20070280943-A1 | SHEDDASE INHIBITORS COMBINED WITH CD30-BINDING IMMUNOTHERAPEUTICS FOR THE TREATMENT OF CD30 POSITIVE DISEASES | CD2, ENTPD1, PDCD10 | ADAM10 19/4885MMP2 1053/4885ERBB2 525/4885 |
| US-20220370440-A1 | 4-SUBSTITUTED PYRROLO[2,3-B]PYRIDINE AS ERBB MODULATORS USEFUL FOR TREATING CANCER | ERBB2, ERBB4, ERBB3 | ADAM10 1869/4885MMP2 4198/4885ERBB2 1/4885 |
| US-20260077015-A1 | CELLULAR IMMUNOTHERAPY COMPOSITIONS AND USES THEREOF | CD47, TNFSF10, CD2 | ADAM10 1342/4885MMP2 2030/4885ERBB2 57/4885 |
| US-12559562-B2 | Treatment of cancer using humanized anti-EGFRvIII chimeric antigen receptor | EGFR, IGSF11, IGLV6-57 | ADAM10 2505/4885MMP2 3964/4885ERBB2 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.